2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Immunology, GVHD, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CMML, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

6184 Interim analysis of a feasibility and usability study for trial, a disease and clinical trial education and resource connection application for patients with newly diagnosed acute leukemia

Andrew Hantel, MD, MPH, Erin Gallagher2, Thomas Walsh, MPH3, Morgan Vitale4, Daniel J DeAngelo, MD, PhD5, Marlise Rachael Luskin, MD, MSCE6, Christopher S Lathan, MD, MPH7, Gregory A. Abel, MD, MPH8
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

Background: 

Patients with acute leukemia participate in acute leukemia clinical trial at low rates. Patient-level causes of non-participation include limited familiarity with acute leukemia at diagnosis, the need for rapid treatment initiation, and hospital-based care, which impede trial knowledge, clinician trust, and informed decision-making (Hantel, Oncologist, 2025). Web applications for addressing these issues are feasible and useful in other cancer types (Meropol, JCO, 2016), but it is not known if this approach is feasible or useful for individuals with acute leukemia.

Methods:

We previously developed an English and Spanish language web application, TRIAL: Tools for Reducing Inequity in Acute Leukemia, for patients with newly diagnosed acute leukemia that provides education and resources about their disease and clinical trials. We report an interim analysis of a single-arm trial with patients at Dana-Farber Cancer Institute assessing its feasibility and usability. Patients ≥18 years with suspected or confirmed diagnosis of acute leukemia were approached prior to treatment initiation. Enrollees were provided with a tablet with application access to use for 14 days and completed pre- and post-surveys. Co-primary endpoints were retention feasibility defined as ≥70% post-test completion, and usability defined as a System Usability Scale median score ≥68 (based on the median score of the median application). Secondary endpoints are application acceptability per the Acceptability of Intervention Measure (scores 4-20, higher scores indicating greater acceptability) and usefulness for treatment decision-making per the Preparation for Decision Making Scale (scores 10-50, higher scores indicate feeling more prepared), and changes in knowledge per the Seven-Item Knowledge Scale (scores 0-7, higher scores indicating more knowledge), trust per the Trust in Medical Researchers Scale (scores 0-48, higher scores indicating more trust), and perception of trials per the Attitudes to Randomized Trials Questionnaire (scores 0-7, higher scores indicating more favorable attitude toward trials). All scores were summarized using medians and interquartile ranges (IQR). Changes in scores from baseline to study completion were compared using the Wilcoxon signed-rank test.

Results:

At the time of data cutoff, 64 patients had been approached, 31 (48%) enrolled, and 29 completed study activities. The most common reasons for not participating were emotional distress and lack of interest. Participants were a median of 66 years old (IQR 50-73), 50% female, 90% non-Hispanic White, and 64% had a bachelor’s or graduate degree. The application was used by 93% of participants, who viewed a median of 4 application pages (IQR 1-21); 54% viewed more than 10 pages. For the retention feasibility primary endpoint, post-tests were completed by 82% of participants. For the usability primary endpoint, the median System Usability Scale score was 67.5 (IQR 57.5-73.8). The median Acceptability of Intervention Measure score was 14 (IQR 13-16) and the median Preparation for Decision Making Scale score was 34 (IQR 30-36). Baseline and 14-day median Seven-Item Knowledge Scale scores were both 4 (IQRs 3-6) with a median change of 0 (p=0.77); Trust in Medical Researchers Scale median scores were 28 and 31 (IQRs 25-34) with a median change of 1 (p=0.44); Attitudes to Randomized Trials Questionnaire median scores were 2 (IQR 1-2) and 3 (1-5) with a median change of 1 (p=0.77). Of the 29 who completed study activities, 14 (48% of study enrollees, 22% of all patients approached) enrolled in a front-line interventional clinical trial.

Conclusions:

In this interim analysis, the TRIAL application demonstrated feasibility and was viewed as acceptable and helpful for decision-making. Usability was near, but did not currently meet, the prespecified benchmark. Although trust and clinical trial attitudes did not change significantly in this sample, the direction of change in both was favorable, supporting continued evaluation in the full cohort.

Andrew Hantel, MD, MPH: Indy Hematology Oncology - Honoraria; Genentech - Consultancy (Includes expert testimony); Jazz - Consultancy (Includes expert testimony)